About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that 12 data presentations, including two oral presentations, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting being held October 24-27 in Brussels, Belgium.

“Our multiple presentations at ESGCT demonstrate uniQure’s continued leadership in advancing important research within the field of gene therapy, as well as highlight our industry-leading expertise in AAV gene therapy manufacturing,” stated Richard Porter, Ph.D., Chief Business and Scientific Officer at uniQure. “We look forward to sharing these presentations that feature our technology and platform experience across numerous programs.”

Specific details on uniQure’s presentations taking place at ESGCT include:

  • Invited Talk Title: Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
    Presenter: Richard Porter, Chief Business and Scientific Officer, uniQure
    Session Title and Location: CNS & sensory diseases II, Session 10a, Shed 2A
    Date and Time: Friday, October 27, 8:30 a.m. GMT+2
  • Title: Gene therapy for C9ORF72-ALS reduces RNA toxicity and ameliorates behavioral phenotype in ALS mouse model
    Presenter: Vanessa Zancanella, Sr. Scientist Global Research, uniQure
    Session Title and Location: CNS & sensory diseases I, Session 2c, Maison de la Poste
    Date and Time: Tuesday, October 24, 17:00 – 19:00 GMT+2
  • Title: Pivotal safety studies for AMT-260, a novel AAV9-dual microRNA-based vector targeting GRIK2 for the treatment of temporal lobe epilepsy (Poster #433)
    Presenter: Nick Pearson, Sr. Director Toxicology & Translational Safety, Non-Clinical, uniQure 
    Poster Session Date and Time: Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 – 21:30 GMT+2
  • Title: Production of low cross-packaging AAV capsid libraries in insect cells (Poster #166)
    Presenter: Bas Bosma, Scientific Leader, Technology Innovation, uniQure
    Poster Session Date and Time: Wednesday, October 25, 18:15 – 19:30, Thursday October 26, 19:30 – 20:30 GMT+2
  • Title: Multiplexed comparison of rationally-designed AAV CNS capsids in vivo (Poster #181)
    Presenter: Elena Pimentel, Scientist, Technology Innovation, uniQure
    Poster Session Date and Time: Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 – 21:30 GMT+2
  • Title: Silence and replace as potential treatment for Alzheimer Disease: in concert lowering toxic APOE and augmenting protective APOE (Poster #049)
    Presenter: Amila Zuko, Scientist, Global Research, uniQure
    Poster Session Date and Time: Wednesday, October 25, 17:00 – 18:15, Thursday, October 26, 20:30 – 21:30 GMT+2
  • Title: Gene therapy for synucleinopathies: Combining vectorized antibody and miRNA-mediated lowering strategies (Poster #430)
    Presenter: Kim Wolzak, Jr. Scientist, Global Research, uniQure
    Poster Session Date and Time: Wednesday, October 25, 18:15-19:30, Thursday, October 26, 19:30-20:30 GMT+2
  • Title: Alpha-synuclein lowering and rescue of motor phenotype by miRNA-based AAV gene therapy in an in vivo Parkinson’s disease rat model (Poster #420)
    Presenter: Rhodé van Westen Erbrink, Scientist, Global Research, uniQure
    Poster Session Date and Time: Wednesday, October 25, 18:15-19:30, Thursday, October 26, 19:30-20:30 GMT+2
  • Title: How uniQure’s modular platform approach drives continuous innovation in AAV gene therapy development and manufacturing (Poster #329)
    Presenter: Erich Ehlert, Director – Process Development – Chemistry, Manufacturing and Controls, uniQure
    Poster Session Date and Time: Wednesday, October 25, 17:00-18:15, Thursday, October 26, 20:30-21:30 GMT+2
  • Title: Accelerating process development by establishing drug substance development platform (Poster #191)
    Presenter: Giorgio Rainone, Bioprocess Technologist, Drug Substance Development, uniQure
    Poster Session Date and Time: Wednesday, October 25, 17:00-18:15, Thursday, October 26, 20:30-21:30 GMT+2
  • Title: High-throughput process development in rAAV drug substance manufacturing (Poster #308)
    Presenter: Yang Jiang, Associate Director, Drug Substance Development, uniQure
    Poster Session Date and Time: Wednesday, October 25, 18:15-19:30, Thursday, October 26, 19:30-20:30 GMT+2
  • Title: Platform development for AAV manufacturing with the Baculovirus Expression Vector System (BEVS) (Poster #193)
    Presenter: Zandra Félix Garza, Project Manager- BPU – Cells, Seeds and Research Supply, uniQure
    Poster Session Date and Time: Wednesday, October 25, 17:00-18:15, Thursday, October 26, 20:30-21:30 GMT+2

About uniQure

uniQure’s mission is to reimagine the future of medicine by delivering innovative cures that transform lives. The recent approvals of our gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. We are now leveraging our modular and validated technology and manufacturing platform to advance a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory mesial temporal lobe epilepsy, amyotrophic lateral sclerosis (ALS), Fabry disease, and other severe diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:

Chiara Russo
Direct: 617-306-9137
Mobile: 617-306-9137
c.russo@uniQure.com
FOR MEDIA:

Tom Malone
Direct: 339-970-7558
Mobile:339-223-8541
t.malone@uniQure.com

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.